Truist Securities Reiterates Buy on HOOKIPA Pharma, Maintains $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Asthika Goonewardene has reiterated a 'Buy' rating on HOOKIPA Pharma (NASDAQ:HOOK) and maintained a $4 price target.
September 06, 2023 | 4:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities has reiterated a 'Buy' rating on HOOKIPA Pharma and maintained a $4 price target.
The reiteration of a 'Buy' rating by Truist Securities indicates a positive outlook for HOOKIPA Pharma. The maintained price target of $4 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100